收稿日期: 2016-04-27
网络出版日期: 2016-06-30
基金资助
国家自然科学基金资助项目(81370262)
Non-coding RNAs and myocardial remodeling
Received date: 2016-04-27
Online published: 2016-06-30
非编码RNA(non-coding RNAs, ncRNAs) 是一类不编码蛋白质的RNA 分子. 相关研究表明, ncRNAs 不仅参与细胞的增殖、凋亡、分化、代谢等生理过程, 还参与疾病的病理过程. 心肌重构(myocardial remodeling)是多种心血管疾病最主要的病理基础. 已有多项研究表明, 心肌重构的发生发展与ncRNAs 的调控息息相关, 近年来针对ncRNAs 在心脏疾病方面的研究也得到了迅猛发展. 对ncRNAs 包括微小RNA(microRNAs, miRNAs)、长链非编码RNA(long non-coding RNAs, lncRNAs)和环形RNA(circular RNAs, circRNAs) 与心肌重构的最新研究进展以及作用机制进行介绍, 旨在寻找新的心脏疾病治疗靶点.
王建勋1, 高金宁1, 丁巍2 . 非编码RNA与心肌重构[J]. 上海大学学报(自然科学版), 2016 , 22(3) : 310 -317 . DOI: 10.3969/j.issn.1007-2861.2016.04.002
Non-coding RNAs (ncRNAs) are a class of RNA molecules that do not encode proteins. Studies show that ncRNAs are not only involved in cell proliferation, apoptosis, differentiation, metabolism and other physiological processes, but also in pathogenesis of diseases. Myocardial remodeling is the main pathological basis of a variety of cardiovascular diseases. Many studies have shown that occurrence and development of myocardial remodeling are closely related to the regulation of ncRNAs. Recent researches of ncRNAs in heart disease have achieved rapid advances. Aimed to look for new targets for heart disease treatment, this paper systematically introduces the latest research progress, mainly in the mechanism of ncRNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in myocardial remodeling.
[1] Capel B, Swain A, Nicolis S, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis [J]. Cell, 1993, 73(5): 1019-1030.
[2] Esteller M. Non-coding RNAs in human disease [J]. Nat Rev Genet, 2011, 12(12): 861-874.
[3] Johnsson P, Lipovich L, Grander D, et al. Evolutionary conservation of long non-coding RNAs; sequence, structure, function [J]. Biochim Biophys Acta, 2014, 1840(3): 1063-1071.
[4] Rinn J L, Kertesz M, Wang J K, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs [J]. Cell, 2007, 129(7): 1311-1323.
[5] Feng J, Bi C, Clark B S, et al. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator [J]. Genes Dev, 2006, 20(11): 1470-1484.
[6] Beltran M, Puig I, Pena C, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition [J]. Genes Dev, 2008, 22(6): 756-769.
[7] Willingham A T, Orth A P, Batalov S, et al. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT [J]. Science, 2005, 309(5740): 1570-1573.
[8] Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency [J]. Nature, 2013, 495(7441): 333-338.
[9] Hansen T B, Jensen T I, Clausen B H, et al. Natural RNA circles function as efficient microRNA sponges [J]. Nature, 2013, 495(7441): 384-388.
[10] Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus [J]. Nat Struct Mol Biol, 2015, 22(3): 256-264.
[11] Ashwal-Fluss R, Meyer M, Pamudurti N R, et al. circRNA biogenesis competes with premRNA splicing [J]. Mol Cell, 2014, 56(1): 55-66.
[12] Zhang P, Kang J Y, Gou L T, et al. MIWI and piRNA-mediated cleavage of messenger RNAs in mouse testes [J]. Cell Res, 2015, 25(2): 193-207.
[13] Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deepsequencing data [J]. Nucleic Acids Res, 2011, 39: D152-D157.
[14] Jiang Q, Wang Y, Hao Y, et al. miR2Disease: a manually curated database for microRNA deregulation in human disease [J]. Nucleic Acids Res, 2009, 37: D98-D104.
[15] Small E M, Olson E N. Pervasive roles of microRNAs in cardiovascular biology [J]. Nature, 2011, 469(7330): 336-342.
[16] Thum T, Condorelli G. Long noncoding RNAs and microRNAs in cardiovascular pathophysiology [J]. Circ Res, 2015, 116(4): 751-762.
[17] Van Rooij E, Sutherland L B, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA [J]. Science, 2007, 316(5824): 575-579.
[18] Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy [J]. Nat Med, 2007, 13(5): 613-618.
[19] Van Rooij E, Sutherland L B, Thatcher J E, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis [J]. Proc Natl Acad Sci USA,
2008, 105(35): 13027-13032.
[20] Karakikes I, Chaanine A H, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling [J]. J Am Heart Assoc, 2013, 2(2): e000078.
[21] Lorenzen J M, Schauerte C, Hubner A, et al. Osteopontin is indispensible for AP1-mediated angiotensinⅡ-related miR-21 transcription during cardiac fibrosis [J]. Eur Heart J, 2015, 36(32): 2184-2196.
[22] Duisters R F, Tijsen A J, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling [J]. Circ Res, 2009, 104(2): 170-178.
[23] Bernardo B C, Gao X M, Winbanks C E, et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function [J]. Proc Natl Acad Sci USA, 2012, 109(43): 17615-17620.
[24] Pan Z, Sun X, Shan H, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factorbeta1 pathway [J]. Circulation, 2012, 126(7): 840-850.
[25] Wei L, Yuan M, Zhou R, et al. MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a [J]. J Cardiovasc Pharmacol, 2015, 65(4): 357-363.
[26] Seok H Y, Chen J, Kataoka M, et al. Loss of microRNA-155 protects the heart from pathological cardiac hypertrophy [J]. Circ Res, 2014, 114(10): 1585-1595.
[27] Yang Y, Del Re D P, Nakano N, et al. miR-206 mediates YAP-induced cardiac hypertrophy and survival [J]. Circ Res, 2015, 117(10): 891-904.
[28] Ucar A, Gupta S K, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy [J]. Nat Commun, 2012, 3: 1078.
[29] Liu F, Li N, Long B, et al. Cardiac hypertrophy is negatively regulated by miR-541 [J]. Cell Death Dis, 2014, 5: e1171.
[30] Wang K, Liu F, Zhou L Y, et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489 [J]. Circ Res, 2014, 114(9): 1377-1388.
[31] Wilkins B J, Dai Y S, Bueno O F, et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy [J]. Circ Res, 2004, 94(1): 110-118.
[32] Molkentin J D, Lu J R, Antos C L, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy [J]. Cell, 1998, 93(2): 215-228.
[33] Kehat I, Molkentin J D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation [J]. Circulation, 2010, 122(25): 2727-2735.
[34] Hunter J J, Chien K R. Signaling pathways for cardiac hypertrophy and failure [J]. N Engl J Med, 1999, 341(17): 1276-1283.
[35] Lin Z, Murtaza I, Wang K, et al. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy [J]. Proc Natl Acad Sci USA, 2009, 106(29): 12103-12108.
[36] Wang K, Long B, Zhou J, et al. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy [J]. J Biol Chem, 2010, 285(16): 11903-11912.
[37] Wang J X, Jiao J Q, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1 [J]. Nat Med, 2011, 17(1): 71-78.
[38] Wang J X, Zhang X J, Li Q, et al. MicroRNA-103/107 regulate programmed necrosis and myocardial ischemia/reperfusion injury through targeting FADD [J]. Circ Res, 2015, 117(4):
352-363.
[39] ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome [J]. Nature, 2012, 489(7414): 57-74.
[40] Han P, Li W, Lin C H, et al. A long noncoding RNA protects the heart from pathological hypertrophy [J]. Nature, 2014, 514(7520): 102-106.
[41] Wang K, Liu C Y, Zhou L Y, et al. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p [J]. Nat Commun, 2015, 6: 6779.
[42] Wang K, Long B, Zhou L Y, et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation [J]. Nat Commun, 2014, 5: 3596.
[43] Viereck J, Kumarswamy R, Foinquinos A, et al. Long noncoding RNA Chast promotes
cardiac remodeling [J]. Sci Transl Med, 2016, 8(326): 326ra322.
[44] Burd C E, Jeck W R, Liu Y, et al. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk [J]. PLoS Genet,
2010, 6(12): e1001233.
[45] Wang K, Long B, Liu F, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223 [J]. Eur Heart J, 2016, pii: ehv713.
[46] Du W W, Yang W, Chen Y, et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses [J]. Eur Heart J, 2016, pii: ehw001.
[47] Wang J X, Gao J, Ding S L, et al. Oxidative modification of miR-184 enables it to target Bcl-xL and Bcl-w [J]. Mol Cell, 2015, 59(1): 50-61.
/
| 〈 |
|
〉 |
